Publication date: Dec 05, 2024
Reactogenicity, the occurrence of vaccine side effects, can impact vaccine acceptance. There is limited data comparing the reactogenicity of COVID-19 vaccines to other routinely used vaccines, such as the meningococcal conjugate vaccine (MenACWY). In a trial of UK adults, participants received a third COVID-19 vaccine dose (NVX-CoV2373, BNT162b2, or mRNA1273) alongside MenACWY as an active control. Compared to MenACWY, we found that mRNA vaccines, particularly mRNA1273, showed the greatest relative increase in side effects, while protein-based NVX-CoV2373 generally elicited similar reactogenicity to MenACWY. These findings suggest that platform type can influence vaccine reactogenicity, and further research is needed to compare COVID-19 vaccines with other routinely administered vaccines.
Open Access PDF
| Concepts | Keywords |
|---|---|
| Covid | COVID-19 |
| Meningococcal | MenACWY |
| Mrna1273 | Meningococcus |
| Routinely | Reactogenicity |
| Vaccine | Vaccine |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | IDO | protein |
| disease | MESH | COVID-19 |